The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)
Open accessAbstract
Background— Aldosterone blockade is recommended for patients with congestive heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction; however, the perceived risk of hyperkalemia may limit implementation of this therapeutic approach. This subanalysis examined the relationship between eplerenone, serum potassium (K + ), and clinical outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Methods and Results— Hospitalized patients with congestive heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction (left ventricular ejection fraction ≤40%) treated with standard therapy were randomized 3 to 14 days after the acute myocardial infarction to additional treatment with eplerenone (25 to 50 mg/d; n=3319) or placebo (n=3313). Patients were excluded if baseline K + was >5.0 mEq/L or serum creatinine was >2.5 mg/dL. In patients receiving standard therapy, the addition of eplerenone resulted in a 4.4% absolute increase in the incidence of K + >5.5 mEq/L, a 1.6% increase of K + ≥6.0 mEq/L, and a 4.7% absolute decrease in hypokalemia (K + <3.5 mEq/L). Four independent baseline predictors of hyperkalemia (defined as ≥6.0 mEq/L) were identified: potassium (K + greater than the median; 4.3 mEq/L), estimated glomerular filtration rate (≤60 mL · min −1 · 1.73 m −2 ), history of diabetes mellitus, and prior use of antiarrhythmic agents. None of these independent baseline risk factors significantly impacted the cardiovascular benefit of eplerenone for reducing all-cause mortality. Conclusions— Use of selective aldosterone blockade with eplerenone within the dose range of 25 to 50 mg/d in post–acute myocardial infarction patients with heart failure and left ventricular systolic dysfunction who are treated with standard therapy improves outcomes without an excess of risk of hyperkalemia (≥6.0 mEq/L) when periodic monitoring of serum K + is instituted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationNolan, J., Batin, P. D., Andrews, R., Lindsay, S. J., Brooksby, P., Mullen, M., Baig, W., Flapan, A. D., Cowley, A., Prescott, R. J., et al. (1998) · Circulation · doi:10.1161/01.cir.98.15.1510 · Cited by 1,179
Cited by
Diabetic kidney disease: a report from an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1296 · Cited by 1,153
Self-citationDiabetic Kidney Disease: A Report From an ADA Consensus Conference
Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.08.001 · Cited by 890
Self-citationFilippatos, G., Anker, S. D., Böhm, M., Gheorghiade, M., Køber, L., Krum, H., Maggioni, A. P., Ponikowski, P., Voors, A. A., Zannad, F., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw132 · Cited by 446
Self-citationAldosterone: effects on the kidney and cardiovascular system
Briet, M., & Schiffrin, E. L. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.30 · Cited by 337
Potassium Homeostasis and Renin-Angiotensin-Aldosterone System Inhibitors
Weir, M. R., & Rolfe, M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07821109 · Cited by 265
Metadata
- Authors
- Pitt, B., Bakris, G., Ruilope, L. M., DiCarlo, L., & Mukherjee, R.
- Venue
- Circulation
- Published
- 2008-10-14
- Volume
- 118
- Issue
- 16
- Pages
- 1643-1650
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2170113769
- Cited by
- 235
- References
- 3
- FWCI
- 15.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). https://app.cochat.ai/papers/10.1161/circulationaha.108.778811
- The paper
- Pitt, B., Bakris, G., Ruilope, L. M., DiCarlo, L., & Mukherjee, R. (2008). Serum Potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. https://doi.org/10.1161/circulationaha.108.778811
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.